Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.

Saved in:
Bibliographic Details
Title: Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.
Authors: Nakashima S; Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Sato K; Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan.; Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan., Niimi Y; Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan.; Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan., Aso S; Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Yasunaga H; Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan., Satake W; Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Iwatsubo T; Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.; National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Source: Journal of Alzheimer's disease : JAD [J Alzheimers Dis] 2026 Jun; Vol. 111 (4), pp. 1510-1515. Date of Electronic Publication: 2026 Apr 21.
Publication Type: Journal Article
Journal Info: Publisher: SAGE Publications Country of Publication: United States NLM ID: 9814863 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1875-8908 (Electronic) Linking ISSN: 13872877 NLM ISO Abbreviation: J Alzheimers Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1875-8908
DOI:10.1177/13872877261443634